Forbes: Promising Anti-Anxiety Treatment Targeting The Endocannabinoid System Gains Steam In Canada

By Jackie Bryant

La Jolla, California-based Artelo Biosciences, Inc. (Nasdaq: ARTL) recently announced that its Canadian subsidiary, Artelo Biosciences Corporation, is the recipient of a Mitacs Accelerate Grant that will allow the company to further its research on ART26.12, a product candidate for the treatment of anxiety, cancer, inflammation, and pain. Mitacs is a Canadian non-profit research organization. The grant is expected to fund 50% of expenses related to preclinical research investigating the drug ART26.12 as a potential treatment for anxiety disorders.

Read more…